NV-INNOGY
At the CONNECTIONS™ Summit at CES – an annual research and industry event hosted by international research firm Parks Associates – the European SmartHome providers eQ-3 and innogy are taking their long-standing cooperation to the next level: in future, they will use a common technological standard, making their systems compatible with each other. This will open up even more options for customers in terms of product variety and possible applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190108005413/en/
The first Homematic IP devices can be linked up with the innogy range from summer 2019. Further products from the wide variety of Homematic IP devices by eQ-3 will steadily follow. eQ-3 assures availability and interoperability of Homematic IP at least until the end of 2030 – so it is worth looking into the future here.
Customers of Homematic IP will then also be able to operate their devices through the innogy hub if they so wish and control them with innogy’s powerful smartphone app with its extremely user-friendly and intuitive interface. The innogy hardware will, in turn, work with the Homematic IP communication standard in the future. innogy customers will feel reassured in the knowledge that they can continue to use their systems as before.
The seamless interoperability of the systems is the next logical step in the collaboration of the two companies that was first established more than nine years ago. innogy by using the "cosIP" protocol and eQ-3 with "Homematic IP" are both already based on IPv6, the next generation of the internet protocol standard. The Homematic IP protocol will be used by both companies in the future.
The two partners ensure a particularly high standard in terms of data efficiency and security. The full innogy SmartHome system has been awarded TÜV certification and Homematic IP is the only smart home platform that has gained VDE certification for its protocol, IT and data security.
Customers also appreciate the market strength of the partners, reflected in the penetration of the German SmartHome market. According to renowned market researcher "Berg Insight" (September 2018), the customer base installed by eQ-3 and innogy in the area of Whole home solutions is larger than the combined share of the next three manufacturers, plus all households with KNX in Europe together.
Printable material as a download at https://news.innogy.com/homematic-ip-and-innogy-smarthome
About innogy SE
innogy SE is a leading German energy
company, with revenue of around €43 billion (2017), more than 42,000
employees and activities in 15 countries across Europe. With its three
business segments Renewables, Grid & Infrastructure and Retail, innogy
addresses the requirements of a modern, decarbonised, decentralised and
digital energy world. Its activities focus on its about 22 million
customers, and on offering them innovative and sustainable products and
services which enable them to use energy more efficiently and improve
their quality of life. The key markets are Germany, the United Kingdom,
the Netherlands and Belgium, as well as several countries in Central
Eastern and South Eastern Europe, especially the Czech Republic, Hungary
and Poland. In renewable power generation, the company is also active in
other regions, e.g. Spain, Italy and the USA, with a total capacity of
3.9 gigawatts. As a leader of innovation in future-oriented fields like
eMobility, we are represented in the international hot-spots of the
technology industry such as Silicon Valley, Tel Aviv and Berlin. We
combine the extensive expertise of our energy technicians and engineers
with digital technology partners, from start-ups to major corporates.
About eQ-3
eQ-3 is a leading provider of innovative
solutions and technologies in the field of home control and consumer
electronics. In 2018, eQ-3 has once again been named European market
leader in the smart home segment for whole-home solutions by renowned
market research institute Berg Insight – for the fourth time running.
eQ-3’s market share with its own systems and OEM products is more than
38% of all installed systems. Its range of over 200 product types is the
broadest in the industry and eQ-3 has supplied more than 27 million
radio-controlled solutions to over 1.4 million households. The design
and product development team with more than 90 developers is based in
Leer in north-west Germany. The company operates its own manufacturing
facility in Zhuhai in southern China. The ELV-/eQ-3 Group has been
family-owned since it was first established. In 2007, eQ-3 AG was carved
out from ELV, which was established in 1978, and can thus look back on
more than 30 years of experience in the smart home segment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005413/en/
Contact:
innogy SE Julika Gang Spokesperson T +49 231 438-22 48 julika.gang@innogy.com
eQ-3 AG Sven Boetcher Director Marketing T +49 491 6008 651 sven.boetcher@eq-3.de
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom